Sanguine Biosciences logo — Bridging the gap between researchers and patients

Sanguine Biosciences

Bridging the gap between researchers and patients

Founded 2010 United States Woburn, United States 116 employees Debt Financing Total: $12.22M Biotechnology, Health Care +1

General Information

Company Name Sanguine Biosciences
Founded Year 2010
Location United States Woburn, United States
Employees 116
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Sanguine Biosciences. To contact Sanguine Biosciences, visit sanguinebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Sanguine Biosciences compare?

A PDF of Sanguine Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Sanguine Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Sanguine Biosciences

Sanguine is a biotechnology and healthcare startup with a mission to accelerate personalized medicine and facilitate biomedical research by empowering patients with their healthcare data. Through direct-to-patient engagement, the company actively bridges the gap between patients and researchers, offering in-home collection of fully annotated biospecimens, apheresis product offerings, and a suite of biorepository services. Since its founding in 2010, Sanguine has supported translational, clinical, and cell & gene therapy research at 35 of the top 40 global pharmaceutical and biotechnology companies, thereby shortening timelines, validating early-stage results, and increasing confidence and refining biomarkers in human trials. Notably, the company received the prestigious designation of a “Great Places to Work” for four consecutive years. In 2022, Sanguine was listed as #2038 on the Inc. 5000 America’s Fastest Growing Private Companies list and achieved recognition on FORTUNE’s 100 Best Small Workplaces and Best Workplaces in Biopharma. Additionally, its studies have been referenced in over 140 publications, appearing in high-impact journals such as Science, Nature, NEJM, Nature Medicine, and Science Translational Medicine. Sanguine has also been featured in popular media outlets including the Fox News Channel, The Washington Post, and Inc. The company's latest investment was a $6.00M Debt Financing round at 31 October 2023, led by Catalio Capital Management. This round of investment showcases confidence from investors in Sanguine's innovative approach to personalized medicine and biomedical research, indicating potential for continued growth and impact in the industry.

Business keywords: Personalized Medicine, Biomedical Research, Biorepository Services, Translational Research, Clinical Research, Cell & Gene Therapy, Patient Engagement, Biospecimen Collection, Apheresis, Biopharma, Data Transparency, Patient Support, Compensation, Observational Studies, Mobile Specimen Collection

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $6.00M 1
Catalio Capital Management
31 Oct 2023
Venture Round Undisclosed 1
BroadOak Capital Partners
09 Jan 2023
Secondary Market Undisclosed 1
Shane Neman
16 Mar 2022
Grant $224.98K 1
National Science Foundation
26 Feb 2019
Venture Round Undisclosed 1
StartUp Health
18 Mar 2018
Venture Round Undisclosed 2
FundersClub, iVentures Asia
01 Jun 2015
Series A $4.00M 1
Seraph Group
25 Nov 2014
Seed Round $2.00M 5
InVent Ventures, Seraph Group +3
23 Feb 2013

Sanguine Biosciences Alternatives & Competitors

View All Alternatives
Sanguine Biosciences vs
Manifold
Manifold United States

The Data Platform for Life Sciences Built for the AI Era

Series A
84 employees
AI, Enterprise Software
Sanguine Biosciences vs
Theragent Inc
Theragent Inc United States

Cell and Gene Therapy Manufacturing

46 employees
Biotechnology, Health Care
Sanguine Biosciences vs
Embleema
Embleema United States

Regulatory-grade real-world data platform for registries, research teams, and patient-driven discove...

Series A
30 employees
Biotechnology, Health Care

FAQ About Sanguine Biosciences

Bridging the gap between researchers and patients
Sanguine Biosciences was founded in 2010.
Sanguine Biosciences is headquartered in Woburn, United States.
Sanguine Biosciences operates in Biotechnology, Health Care and Life Sciences. Its work centres on Personalized Medicine, Biomedical Research, Biorepository Services and Translational Research.
Sanguine Biosciences has approximately 116 employees.
Sanguine Biosciences has completed 8 funding rounds, raising a total of $12.22M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Sanguine Biosciences include Manifold, Theragent Inc, Embleema, Sano Genetics, Evia Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sanguine Biosciences and Manifold are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Sanguine Biosciences, https://bouncewatch.com/company/sanguine, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes